Cargando…
A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents
Anti‐IgE treatments, such as omalizumab, have shown promising effects in allergy treatment. Our previous work has shown that individualized omalizumab treatment (OT) allows a safe initiation and rapid up‐dosing of peanut oral immunotherapy (OIT) in peanut‐allergic adolescents. However, the broader i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988572/ https://www.ncbi.nlm.nih.gov/pubmed/33244763 http://dx.doi.org/10.1111/sji.13005 |
_version_ | 1783668808933703680 |
---|---|
author | van der Heiden, Marieke Nopp, Anna Brandström, Josef Carvalho‐Queiroz, Claudia Nilsson, Caroline Sverremark‐Ekström, Eva |
author_facet | van der Heiden, Marieke Nopp, Anna Brandström, Josef Carvalho‐Queiroz, Claudia Nilsson, Caroline Sverremark‐Ekström, Eva |
author_sort | van der Heiden, Marieke |
collection | PubMed |
description | Anti‐IgE treatments, such as omalizumab, have shown promising effects in allergy treatment. Our previous work has shown that individualized omalizumab treatment (OT) allows a safe initiation and rapid up‐dosing of peanut oral immunotherapy (OIT) in peanut‐allergic adolescents. However, the broader immunological effects of this OT are incompletely understood. In this pilot study, we longitudinally followed the total B‐ and T‐cell immunity during OT, using flow cytometry, ELISpot and ELISA. Peripheral blood mononuclear cells (PBMCs) and plasma were collected from participants (n = 17) at several timepoints during treatment, before starting OT (baseline), prior to starting OIT during OT (start OIT) and at maintenance dose OIT prior to OT reduction (maintenance). OT did not affect the total B‐cell compartment over treatment time, but our results suggest an association between the OT dosage scheme and the B‐cell compartment. Further, in vitro polyclonal T‐cell activation at the different timepoints suggests a cytokine skewing towards the Th1 phenotype at the expense of Th2‐ and Th9‐related cytokines during treatment. No differences in the frequencies or phenotype of regulatory T cells (Tregs) over treatment time were observed. Finally, plasma chemokine levels were stable over treatment time, but suggest elevated gut homing immune responses in treatment successes during the treatment as compared to treatment failures. The novel and explorative results of this pilot study help to improve our understanding on the immunological effects of OT used to facilitate OIT and provide guidance for future immunological investigation in large clinical trials. |
format | Online Article Text |
id | pubmed-7988572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79885722021-03-25 A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents van der Heiden, Marieke Nopp, Anna Brandström, Josef Carvalho‐Queiroz, Claudia Nilsson, Caroline Sverremark‐Ekström, Eva Scand J Immunol Human Immunology Anti‐IgE treatments, such as omalizumab, have shown promising effects in allergy treatment. Our previous work has shown that individualized omalizumab treatment (OT) allows a safe initiation and rapid up‐dosing of peanut oral immunotherapy (OIT) in peanut‐allergic adolescents. However, the broader immunological effects of this OT are incompletely understood. In this pilot study, we longitudinally followed the total B‐ and T‐cell immunity during OT, using flow cytometry, ELISpot and ELISA. Peripheral blood mononuclear cells (PBMCs) and plasma were collected from participants (n = 17) at several timepoints during treatment, before starting OT (baseline), prior to starting OIT during OT (start OIT) and at maintenance dose OIT prior to OT reduction (maintenance). OT did not affect the total B‐cell compartment over treatment time, but our results suggest an association between the OT dosage scheme and the B‐cell compartment. Further, in vitro polyclonal T‐cell activation at the different timepoints suggests a cytokine skewing towards the Th1 phenotype at the expense of Th2‐ and Th9‐related cytokines during treatment. No differences in the frequencies or phenotype of regulatory T cells (Tregs) over treatment time were observed. Finally, plasma chemokine levels were stable over treatment time, but suggest elevated gut homing immune responses in treatment successes during the treatment as compared to treatment failures. The novel and explorative results of this pilot study help to improve our understanding on the immunological effects of OT used to facilitate OIT and provide guidance for future immunological investigation in large clinical trials. John Wiley and Sons Inc. 2020-12-15 2021-04 /pmc/articles/PMC7988572/ /pubmed/33244763 http://dx.doi.org/10.1111/sji.13005 Text en © 2020 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Human Immunology van der Heiden, Marieke Nopp, Anna Brandström, Josef Carvalho‐Queiroz, Claudia Nilsson, Caroline Sverremark‐Ekström, Eva A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents |
title | A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents |
title_full | A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents |
title_fullStr | A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents |
title_full_unstemmed | A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents |
title_short | A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents |
title_sort | pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents |
topic | Human Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988572/ https://www.ncbi.nlm.nih.gov/pubmed/33244763 http://dx.doi.org/10.1111/sji.13005 |
work_keys_str_mv | AT vanderheidenmarieke apilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT noppanna apilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT brandstromjosef apilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT carvalhoqueirozclaudia apilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT nilssoncaroline apilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT sverremarkekstromeva apilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT vanderheidenmarieke pilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT noppanna pilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT brandstromjosef pilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT carvalhoqueirozclaudia pilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT nilssoncaroline pilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents AT sverremarkekstromeva pilotstudytowardstheimmunologicaleffectsofomalizumabtreatmentusedtofacilitateoralimmunotherapyinpeanutallergicadolescents |